While additional studies are required to validate IL-32 as a predictive or prognostic biomarker and to translate IL-32 as a tumor immunotherapy to the clinic, the therapeutic efficacy of this cytokine for melanoma treatment has been demonstrated in this study. Here, IL32 is linked to melanoma.